Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Sponsor
Fudan University
Study ID
NCT05265793
Phase
PHASE2
Status
Unknown

Conditions

  • Carcinosarcoma
  • PD-1 Immunotherapy
  • Sarcomatoid Carcinoma
  • VEGFR-TKI

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab Combined With Apatinib — DRUG
    After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur

Study Details

This study is to explore the treatment of advanced sarcomatoid carcinoma or Carcinosarcoma with Carrelizumab combined with Apatinib, in order to provide guidance and experience for new combined therapy in clinic.

Key Dates

Start date
Nov 21, 2021
Status verified
Mar 2022
Primary completion
Mar 30, 2023
Completion
Jun 30, 2023

Study Design

Enrollment
45 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab Combined With Apatinib
    Apatinib tablets: 250mg qd.po, 4 weeks as a cycle, continuous medication until disease progression, death or intolerable toxicity; Camrelizumab: administered intravenously with a fixed dose of 200mg, administered intravenously (without preventive medication), each infusion for 30min (no less than 20min, no more than 60min), administered once every two weeks until disease progression, death or intolerable toxicity. The maximum period is 2 years. The curative effect was evaluated every 8 weeks.

Primary Outcome Measure

ORR [ Time Frame: the rate of patients with CR and PR, through study completion, an average of 1 year ]

Central Contacts

Related Studies